




**New Day in Medicine**  
**Новый День в Медицине**

**NDM**



# TIBBIYOTDA YANGI KUN

Ilmiy referativ, marifiy-ma'naviy jurnal



**AVICENNA-MED.UZ**



ISSN 2181-712X.  
EiSSN 2181-2187

**2 (40) 2022**

**Сопредседатели редакционной  
коллегии:**

**Ш. Ж. ТЕШАЕВ,  
А. Ш. РЕВИШВИЛИ**

**Ред. коллегия:**

М.И. АБДУЛЛАЕВ  
А.А. АБДУМАЖИДОВ  
А.Ш. АБДУМАЖИДОВ  
М.М. АКБАРОВ  
Х.А. АКИЛОВ  
М.М. АЛИЕВ  
С.Ж. АМИНОВ  
Ш.Э. АМОНОВ  
Ш.М. АХМЕДОВ  
Ю.М. АХМЕДОВ  
Т.А. АСКАРОВ  
Ж.Б. БЕКНАЗАРОВ (главный редактор)  
Е.А. БЕРДИЕВ  
Б.Т. БУЗРУКОВ  
Р.К. ДАДАБАЕВА  
М.Н. ДАМИНОВА  
К.А. ДЕХКОНОВ  
Э.С. ДЖУМАБАЕВ  
А.Ш. ИНОЯТОВ  
С. ИНДАМИНОВ  
А.И. ИСКАНДАРОВ  
С.И. ИСМОИЛОВ  
Э.Э. КОБИЛОВ  
Д.М. МУСАЕВА  
Т.С. МУСАЕВ  
Ф.Г. НАЗИРОВ  
Н.А. НУРАЛИЕВА  
Б.Т. РАХИМОВ  
Ш.И. РУЗИЕВ  
С.А. РУЗИБОВЕВ  
Ж.Б. САТТАРОВ  
Б.Б. САФОВЕВ (отв. редактор)  
И.А. САТИВАЛДИЕВА  
М.М. ТАДЖИЕВ  
А.Ж. ХАМРАЕВ  
А.М. ШАМСИЕВ  
А.К. ШАДМАНОВ  
Н.Ж. ЭРМАТОВ  
Б.Б. ЕРГАШЕВ  
Н.Ш. ЕРГАШЕВ  
И.Р. ЮЛДАШЕВ  
М.Ш. ХАКИМОВ  
К.А. ЕГЕЗАРЯН (Россия)  
DONG JINCHENG (Китай)  
КУЗАКОВ В.Е. (Россия)  
Я. МЕЙЕРНИК (Словакия)  
В.А. МИТИШ (Россия)  
В.И. ПРИМАКОВ (Беларусь)  
О.В. ПЕШИКОВ (Россия)  
А.А. ПОТАПОВ (Россия)  
А.А. ТЕПЛОВ (Россия)  
Т.Ш. ШАРМАНОВ (Казахстан)  
А.А. ЩЕГОЛОВ (Россия)  
Prof. Dr. KURBANHAN MUSLUMOV (Azerbaijan)  
Prof. Dr. DENIZ UYAK (Germany)

**ТИББИЁТДА ЯНГИ КУН  
НОВЫЙ ДЕНЬ В МЕДИЦИНЕ  
NEW DAY IN MEDICINE**

*Илмий-рефератив, маънавий-маърифий журнал  
Научно-реферативный,  
духовно-просветительский журнал*

**УЧРЕДИТЕЛИ:**

**БУХАРСКИЙ ГОСУДАРСТВЕННЫЙ  
МЕДИЦИНСКИЙ ИНСТИТУТ  
ООО «ТИББИЁТДА ЯНГИ КУН»**

Национальный медицинский  
исследовательский центр хирургии имени  
А.В. Вишневского является генеральным  
научно-практическим  
консультантом редакции

Журнал был включен в список журнальных  
изданий, рецензируемых Высшей  
Аттестационной Комиссией  
Республики Узбекистан  
(Протокол № 201/03 от 30.12.2013 г.)

**РЕДАКЦИОННЫЙ СОВЕТ:**

М.М. АБДУРАХМАНОВ (Бухара)  
Г.Ж. ЖАРЫЛКАСЫНОВА (Бухара)  
А.Ш. ИНОЯТОВ (Ташкент)  
Г.А. ИХТИЁРОВА (Бухара)  
Ш.И. КАРИМОВ (Ташкент)  
У.К. КАЮМОВ (Ташкент)  
Ш.И. НАВРУЗОВА (Бухара)  
А.А. НОСИРОВ (Ташкент)  
А.Р. ОБЛОКУЛОВ (Бухара)  
Б.Т. ОДИЛОВА (Ташкент)  
Ш.Т. УРАКОВ (Бухара)

**2 (40)**

**2022**

*март-апрель*

[www.bsmi.uz](http://www.bsmi.uz)

<https://newdaymedicine.com>

E: [ndmuz@mail.ru](mailto:ndmuz@mail.ru)

Тел: +99890 8061882

<i>Fayzieva M.F., Khasanova M.I., Iskandarova V.V.</i> STATE OF HEALTH OF PERSONS ENGAGED IN THE MANUFACTURE OF PRODUCTS FROM MOLYBDENUM IN THE CONDITIONS OF UZBEKISTAN.....	266	<i>H.S. Abdurazzakhov, S.R. Baymakov, D.B. Adilbekova</i> MORPHOFUNCTIONAL STATE OF THE SMALL INTESTINE IN EXPERIMENTAL INTESTINAL INSUFFICIENCY AND ITS DRUG CORRECTION.....	335
<i>Shokirov Kh.Sh., Kamalov T.T.</i> BIOCHEMICAL CHARACTERISTICS OF PATIENTS WITH SEVERE COMPLICATIONS OF THE DIABETIC FOOT SYNDROME (ULCER, GANGRENE, AMPUTATION) ASSOCIATED WITH CHRONIC KIDNEY DISEASE.....	272	<i>Daminova K.M., Islamova M.S.</i> FEATURES OF BLOOD PRESSURE VARIABILITY DURING CKD.....	341
<i>Akhmedova M.D., Niyazova T.A., Anvarov J.A., Zaylobidinov B.Z.</i> MOLECULAR STUDY OF LONG-TERM CELL PARASITISM OF BRUCELL.....	280	<i>Elmuradova A.A.</i> CLINICAL-IMMUNOLOGICAL TRANSITION FEATURES OF COVID-19 IN CHILDREN.....	347
<i>Niyozova T.A., Karimova M.T., Zubaydullayeva M.T., Kholmurodov D. M.</i> COMPARATIVE STUDY OF CLINICAL CHARACTERISTICS OF INTESTINAL PARASITOSIS.....	285	<i>Rakhmatullaeva Sh.B., Ganieva S.K.</i> FEATURES OF ACUTE INTESTINAL INFECTIONS IN CHILDREN WITH A PREMORBID BACKGROUND.....	348
<i>Ahmedova M. J., Khodjaev N. I., Khodjaev B. J.</i> ON THE IMPLEMENTATION OF THE STRATEGY "DIGITAL UZBEKISTAN - 2030".....	291	<i>Atabekov N.S., Yunusov M.M., mAtahajiyev M.S.</i> SOME CLINICAL CHANGES IN THE EARLY NEONATAL PERIOD IN NEWBORNS BORN TO HIV-INFECTED MOTHERS.....	355
<i>Jalilova A.S., Mukhtorova Sh.A., Khojiev D.Ch., Vaxobov A.A.</i> CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF PATIENTS WITH SEVERE SARS- COV-2-ASSOCIATED PNEUMONIA.....	296	<i>Ibrakhimova H.R., Oblokulov A.R., Yitmasova T.D.</i> ANALYSIS OF DIAGNOSTIC INDICATORS OF PARASITIC DISEASES.....	359
<i>Urokov Sh. T., Babanazarov U. T., Eshonov O. Sh.</i> PECULIARITIES OF THE STATE OF THE LIVER IN PATIENTS WITH POST-COVID-19.....	300	<i>Oblokulov A.R., Kholov U.A., Djalilova A.S.</i> MICROBIOLOGICAL INDICATORS OF PATIENTS WITH CONFIRMED COVID-19 INFECTION.....	363
<i>Khodjaev N. I., Ahmedova M. J., Khodjaev B. J.</i> SOME FEATURES OF COMPREHENSIVE DEVELOPMENT OF HEALTHCARE SYSTEM IN OUR COUNTRY.....	304	<i>Khushvakova N.Zh., Bakiev Sh.Sh., Makhmudova L.I.</i> METHODS OF IMPROVING THE DIAGNOSIS OF CHRONIC RECURRENT RHINOSINUSITIS.....	370
<i>Tuychiev L.N., Maqsudova Z.S., Abidov A.B. , Kolton V.A.</i> SUMMARY STUDYING THE INCIDENCE OF FOOD TOXIC INFECTION, INCLUDING BOTULISM IN A COMPARATIVE ASPECT.....	309	<i>Abidov U. O., Khaydarov A. A.</i> COMPLEX TWO-STAGE TREATMENT OF PATIENTS WITH OBSTRUCTIVE JAUNDICE SYNDROME OF BENIGN GENESIS.....	375
<i>Khamidova N. K.</i> CLINICAL-NEUROLOGICAL AND IMMUNOLOGICAL INDICATORS CHILDREN WITH HELMINTHIC INVASION.....	314	<i>Ashurova N.G., Ismatova M.N.</i> MENSTRUAL DISORDERS IN ADOLESCENT GIRLS WITH INSULIN RESISTANCE.....	378
<i>Yarmukhamedova N. A., Tirkashev O. S., Matyakubova F. E., Rabbimova N. T.</i> CLINICAL FEATURES OF CONTEMPORARY SCARLET FEVER COURSE (IN TERMS OF SAMARKAND REGION).....	319	<i>Kamalova M. K., Samatov R. R., Jumaev L.R.</i> RESULTS OF EVALUATION BY THE CLINIC OF THE EFFECTIVENESS OF REVENTION AND TREATMENT OF ACUTE INFLAMMATORY DISEASES OF THE SALIVARY GLANDS.....	383,
<i>Avdeeva M.G., Oblokulov A.R. , Ergashov M.M.</i> PROCALCITONIN AS A PREDICTOR OF ANTIBACTERIAL THERAPY FOR COVID-19.....	323	<i>Yoriyev Shokhrub Anvar ugli, Kamalova Mekhrinis Kılıchevna</i> OPTIMIZATION OF COMPLEX TREATMENT OF GUM EPULIS BY MEANS OF MAGNETIC-INFRARED-LASER RADIATION.....	388
<i>Lipartia M.G., Ashurova D.T., Daminova M.N.</i> NON-HODGKIN'S LYMPHOMA IN CHILDREN.....	330	<i>Shakhlo Salomovna Kodirova</i> FEATURES OF THE TREATMENT OF PSYCHOLOGICAL DISORDERS IN PATIENTS WITH HEART DISEASES.....	392
<i>Daminova Kh.M., Saidvaliev F.S.</i> ASSESSMENT OF OLFATORY FUNCTION IN THE STUDY GROUPS AND THEIR ROLE IN THE PROGRESSION OF THE DISEASE.....	332	<i>Makhmudova L.I., Sharipov Zh.N.</i> ASSESSMENT OF RISK FACTORS FOR IRRITABLE BOWEL SYNDROME.....	396
		<i>Nazarov Jalolitdin Sulton Erkinovich</i> LACONICISM, DEDUCTION AND CASES IN TEACHING PRACTICE.....	401
		<i>Rakhimov Sh.Sh., Sharopov S.G., Ashurova N.G.</i> IMPROVING THE EFFICIENCY OF LOCAL SOFT TISSUE PLASTIC SURGERY IN EXPRESS IMPLANTATION.....	407



UDC 616.98:579.841.93-078:577

**BRUTSELLANING UZOQ MUDDATLI HUYAYRA ICHI PARAZITIZMINI MOLEKULAR  
O'RGANISH**  
(adabiyotlar sharxi)

*Axmedova M.D., Niyozova T.A., Anvarov J.A., Zaylobidinov B.Z.*

Toshkent Tibbiyot Akademiyasi, O'zbekiston

✓ **Rezume**

*Makroorganizmga nisbatan spetsifik evolyutsiya brucellaga hujayra ichida turg'un saqlanishga, makroorganizmning hujayraviy immunitetini o'ziga xos boshqarib immun hujayralarda uzoq vaqt persistensiyasiga imkon beradi. Brucella evolyutsiyasi hujayra ichida saqlanishga yo'naltirilgan bo'lib asosan hujayra lizosomal fermentlariga nisbatan chidamlilikka bog'liq. Maqolada brutselloz qo'zg'atuvchisining hujayra ichida persistensiyasini ta'minlovchi molekulyar mexanizmlar ko'rsatilgan. Bakteriyaning hujayra ichida saqlanishi molekulyar mexanizmlarini tushunish bizga brucella bakteriyasi ustidan epidemiologik nazoratni oshirishga, profilaktika va davolashning yangi usullari va vositalarini ishlab chiqishga katta yordam beradi.*

*Kalit so'lar: Brutselloz, Brucella, makroorganizm, hujayra ichi parazitizmi, immunitet, sitokinlar, gen.*

**МОЛЕКУЛЯРНОЕ ИССЛЕДОВАНИЕ ДОЛГОВРЕМЕННОГО КЛЕТОЧНОГО  
ПАРАЗИТИЗМА БРУЦЕЛЛЫ**  
(обзор литературы)

*Ахмедова М.Д., Ниёзова Т.А., Анваров Ж.А., Зайлобидинов Б.З.*

Ташкентская медицинская академия, Узбекистан

✓ **Резюме**

*Специфическая эволюция по отношению к макроорганизму позволяет бруцеллам оставаться стабильными внутри клетки, длительно сохраняться в иммунных клетках за счет регуляции клеточного иммунитета макроорганизма. Эволюция бруцелл направлена на внутриклеточном паразитировании и в основном обусловлена устойчивостью к клеточным лизосомальным ферментам. В статье показаны молекулярные механизмы, обеспечивающие внутриклеточную персистенцию возбудителя бруцеллеза. Понимание молекулярных механизмов внутриклеточного накопления бактерий в значительной степени поможет нам усилить эпидемиологический контроль над бруцеллезными бактериями и разработать новые методы и средства диагностики и лечения.*

*Ключевые слова: бруцеллез, бруцеллы, макроорганизм, внутриклеточный паразитизм, иммунитет, цитокины, гены.*

**MOLECULAR STUDY OF LONG-TERM CELL PARASITISM OF BRUCELLA**  
(review)

*Akhmedova M.D., Niyazova T.A., Anvarov J.A., Zaylobidinov B.Z.*

Tashkent Medical Academy, Uzbekistan

✓ **Resume**

*Specific evolution in relation to the macroorganism allows brucella to remain stable inside the cell, long-term persistence in immune cells by regulating the cellular immunity of the macroorganism. The evolution of Brucella is aimed at intracellular storage and is mainly due to resistance to cellular lysosomal enzymes. The article shows the molecular mechanisms that provide intracellular persistence of the brucellosis pathogen. Understanding the molecular mechanisms of intracellular storage of bacteria will greatly help us to increase epidemiological control over brucella bacteria and to develop new methods and means of prevention and treatment.*

*Keywords: Brucellosis, Brucella, macroorganism, intracellular parasitism, immunity, cytokines, genes.*

## Dolzarbligi

Brutsellyoz – zoonoz infeksiyon kasallik bo‘lib, *Brucella* oilasiga mansub bakteriyalar tomonidan chaqirilib, qishloq xo‘jaligi va yovvoyi hayvonlardan odamga yuqadi va aksariyat holatlarda mehnatga layoqatli yoshdagi bemorlarda surunkali kechish va keyinchalik nogironlikka sabab bo‘lishi bilan dolzarbligi tavsiflanadi. *Brucella* oilasi bakteriyalari fakultativ hujayra ichi patogenlar bo‘lib, ular immunitet hujayralarida saqlanib qolishi hisobiga uzoq yillar davomida surunkali kechishi mumkin [1]. Brutsellyoz hozirgi kunda ham butun dunyoda aholi salomatligiga xavf soluvchi dolzarb muammolardan biri hisoblanadi. Dunyoda bu kasallik bilan kasallanish ko‘rsatkichlari xanuz yuqori darajada saqlanib qolmoqda. Jahon sog‘liqni saqlash tashkilotining (JSST) ma‘lumotlariga ko‘ra, dunyoda har yili insonlarda 500.000 dan ortiq yangi tashxis qo‘yilgan brutsellyoz holatlari qayd etiladi. Ammo asl xolat 1,5 million atrofida deb baxolanadi [2].

*Brucella* xayvonlardan odamlarga muloqot, alimantar va aerogen (havo-chang) yo‘llar orqali yuqadi, hamda odam organizmida uzoq muddat hujayra ichida parazitlik qiladi. Brutsellyoz butun dunyoda sog‘liqni saqlash tizimida dolzarb muammoligicha qolmoqda. Bunga sabab esa kasallikning surunkali kechishga moyilligi hamda surunkali formalarning antibiotikaterapiyaga chidamliligidir [3, 4, 5, 6, 7, 8]. Surunkali kechish oqibatida esa ishga layoqatli aholi qatlamida nogironlik yuzaga keladi. Juda kam hollarda kasallik bemorlardan sog‘lomlarga yuqishi kuzatiladi [9]. Natijada kasallik nafaq tibbiy balki ijtimoiy-siyosiy ko‘rinishga ega bo‘ladi [7, 8].

Inson uchun nisbatan yuqori patogenlikka ega turlar sifatida *Br. melitensis* (asosiy xo‘jayini kichik shoxli hayvonlar – qo‘y, echki), *Br. suis* (cho‘chqa, quyon, bug‘u, kemiruvchilar), *Br. abortus* (yirik shoxli hayvonlar – sigir) va *Br. canis* (itlar)lar deb hisoblanadi. Kasallik o‘zida qo‘zg‘atuvchi saqlagan xayvon maxsulotlari va chiqindilari bilan to‘g‘ridan to‘g‘ri kontakt orqali ham yuqadi [6, 10, 11]. Ba‘zi adabiyotlarda bemorlardan sog‘lomlarga yuqishi ham aytiladi. [9].

*Brucella* bakteriyasida makroorganizmining makrofaglar, dendritik hujayralari, platsentar trofoblast hujayralariga nisbatan yuqori darajada tropizmi mavjud. Bundan tashqari yana sut emizuvchilarning boshqa bir qancha hujayralariga nisbatan moyillik namoyon qiladi: endotelial hujayralar, epitelial hujayralar, fibroblastlar, mikroglia hujayralari [1, 7].

Ovqat hazm qilish tizimi orqali organizmga tushgan brutsella makroorganizm shilliq qavatidan o‘tgach dendritik hujayralar hamda makrofaglar tomonidan fagotsitozga uchraydi, bu jarayonda ushbu hujayralar yuzasidagi aktin tolalari to‘plami qatnashadi. Bakteriya bilan o‘zaro tasirdan so‘ng ushbu to‘plamlar hujayra devorining invaginatsiyasiga sabab bo‘ladi va birlamchi fagosoma hosil bo‘ladi. Opsonlangan brutsellalar komplement orqali hujayra ichiga yo‘nalgan bir vaqtda opsonlanmagan brutsellalar lektin va fibronektin retseptorlari bilan ta‘sirlashadi. Opsionlanmagan brutsellalar hujayra ichida yashab qolishi mumkin, bundan farqli o‘laroq opsonlangan yoki makrofagning IFN-gamma faollashuvi orqali hujayra ichiga tushgan brutsella makrofag ichida lizisga uchraydi [8]. Lipid tolalari makrofaglarning hujayra membranasida xolesteringa boy mikrodomenlarni o‘z ichiga oladi, ushbu mikrodomenlar brutsellaning hujayra ichiga tushishida va uning hujayra ichida yo‘naltirilgan harakatiga yordam beradi [7].

Brutsellani internalizatsiyasidan so‘ng, brutsellani o‘z ichiga olgan vakuola - BCV hosil bo‘ladi. Fagotsitozlangan brutsellalarning 90% ga yaqini kislorodli erkin radikallar, azot oksidi va fagolizosomalar ichidagi fermentlarning bakteritsid ta‘sirida nobud bo‘ladi. Qolgan bakteriyalar ushbu bakteritsid omillarni yengib, erta va kech endosomalar bilan o‘zaro ta‘sirlashadi va lizosoma bilan vaqtincha qisqa muddatli qo‘shilish jarayonidan so‘ng lizosomal oqsillarni faol ravishda chiqarib tashlashi va BCVni endoplazmatik retikulum (ER) ga yo‘naltirishi mumkin, ERda esa hujayra ichki resurslaridan foydalangan holda brutsella erkin ko‘payadi [12, 13]. BCV dagi kislotalilikning oshishi bakteriyalarga zarar etkazmaydi, ammo infeksiyaning dastlabki bosqichlarida hujayra ichida omon qolish uchun zarur bo‘lgan bakterial genlarining ekspressiyasini yuzaga keltiradi [14, 15].

Hujayra ichidagi ko‘payish davom etishi va bakteriyaning hujayra ichida saqlanib qolishi uchun *Brucella* bir qator vakuol o‘zgarishlarini boshdan kechiradi. Bu o‘zgarish jarayonida dastlabki endotsitar eBCV vakuola replikativ rBCV vakuolaga aylanadi, jarayon so‘ngida esa avtofag aBCV vakuolasi bilan yakunlanadi. Avtofagiya bilan bog‘liq bo‘lgan makroorganizm oqsillari BECLIN1, PI3K, ULK1 va Atg14L BCV vakuolasining biogenezida muhim rol o‘ynaydi va yakunda organizmga bakteriyalarning chiqishi bilan tugovchi brutsellaning hujayra ichi hayot siklining tugashiga tasir ko‘rsatadi [16, 17]. Fagotsitozning yuqorida keltirib o‘tilgan xususiyatlari brutsellaning makroorganizm hujayrasida va umuman olganda organizmning o‘zida saqlanib turishiga sharoit yaratadi.

Hujayra membranalarida (TLR) yoki sitozolda (NLR) mavjud bo'lgan retseptorlar bakteriyalar uchun xos bo'lgan tuzilmalarni aniqlashga qodir: lipopolisaxaridlar, lipoproteinlar va flagellin, bu esa o'z navbatida yallig'lanishga qarshi dastlabki reaksiyaning paydo bo'lishiga olib keladi. *Brucella*, TLR va NLR retseptorlari ishtirok etadigan tanib olish jarayonidan yashirinish uchun passiv va aktiv molekulyar mexanizmlarga ega. *Brucella* lipopolisaxarid tuzilishi enterobakteriyalarning lipopolisaxaridi (C12-C16) bilan solishtirganda ko'proq yog' kislotasi qoldig'ini (C28) o'z ichiga olgan lipid A xususiyatlariga ega va bu modifikatsiya uning TLR4 retseptorlari bilan o'zaro ta'sirini sezilarli darajada kamaytiradi va TLR4 retseptorlari orqali signalizatsiya yo'llari orqali tanib olishdan qochishga imkon beradi [14, 18]. TLR4 agonistining faolligi lipopolisaxarid yadrosining glikozillanish yo'li bilan TLR4 MD-2 retseptorlari va brutsella lipopolisaxaridi o'rtasidagi o'xshashlikni kamaytiradi [19, 20].

Komplementning faollashuvi va bakterial xoslikka ega TLR lar birgalikda ishlaydi va makroorganizmga xavf omiliga nisbatan mos javob berishida alohida o'rin egallaydi (neytrofillar oqimi va boshqalar) [22]. Komplement sistemasi bakteriya hujayra devoridagi lipopolisaxarid bilan o'zaro tasirlanganda ishga tushadi [14, 18, 23]. *Brucella* lipopolisaxaridi tarkibida gomopolimer qoldiqlardan tashkil topgan O-polisaxaridi mavjud bo'lib, bu polimer C3 komplement sistemasi bilan to'liq birikmaydi, bu jarayon C3a va C5a komplement tizimining yallig'lanishga qarshi mahsulotlarini ishlab chiqarishini to'xtatadi [14, 18, 23].

*Brucella* harakatsiz bakteriya bo'lsada, uning genomlari noma'lum funksiyaga ega noan'anaviy flagellin (ipchalar) tarkibiy qismlarini kodlaydi, TLR5 retseptorida ushbu flagellinni tanib olish uchun zarur bo'lgan domen yo'qligi sababli bakteriya sezilmasdan qoladi [18, 15]. Biroq, sitozolik NLCR4 retseptorlari brutsella flagellinini aniqlay olishi va *in vivo* ravishda infeksiyani nazorat qilish uchun muhim ekanligi ko'rsatilgan [21]. TLR4 ga qo'shimcha ravishda TLR2 va TLR9 signal yo'li brutsellyoz infeksiyasini aniqlashda ishtirok etadi [24].

Brucellaning immun tizim orqali tanib olinishiga faol to'sqinlik qilishi quyidagi oqsillarning ishlab chiqarilishi bilan bog'liq: *Br. abortus*da TIR domeni Btp1/BtpA, *Br. melitensis*da TcpB. Btp1 va TcpB MyD88 adapterining (MAL) o'tkazuvchanlik funksiyasiga salbiy ta'sir qiladi, bu esa TLR2 va TLR4 signalizatsiyasi uchun zarurdir [25, 26]. Natijada, bu oqsillar dendritik hujayralarning yetilishini va yallig'lanishga qarshi sitokinlarni ishlab chiqarishni ingibirleydi, bu esa brutsellaning uzoq muddatli saqlanishi yordam beradi.

Brutsellalarning barcha turlari virB1-virB12 genlari tomonidan kodlanadigan T4SS (IV turdagi sekretsiya tizimi) muhim virulentlik omiliga ega. Ushbu omil bakteriyaga hujayra ichida omon qolishga imkon yaratadi [18, 27, 28].

T4SS ning hal qiluvchi roli virB genlari mutatsiyaga uchragan brutsella bakteriyalarining sichqon [29, 30] va echki modellarida [31] *in vivo* hujayra ichida ko'payish qobiliyatiga ega emasligida tasdiqlangan. T4SS shuningdek, *Brucella* uchun maxsus ER bilan bog'liq replikasiya sohasini yaratishda ishtirok etadi, virB geni mutatsiyaga uchragan bakteriyalar esa makrofag lizosomalari ichida parchalanadi [3, 32].

T4SS transmembrana oqsilli "pushka" ni hosil qiladi, bu protein effektor molekularini makroorganizm hujayrasi sitoplazmasiga ko'chirishni amalga oshiradi, bu ularning turli funksiyalarini ta'minlaydi va hujayra ichidagi infeksiyani rivojlanishi va saqlanishiga ta'sir qiladi. Ko'pgina tadqiqotlarda bir necha o'nlab *Brucella* T4SS effektor oqsillari makroorganizm sitoplazmasiga ko'chirilishi paytida aniqlangan [7, 33, 34, 35, 36]. T4SS oqsillarining kasallikni qo'zg'atish uchun va albatta hujayra ichida saqlanib qolishi uchun bevosita va bilvosita muhim ekani bir qancha ilmiy ishlarda tasdiqlangan [5, 10, 34, 35, 36].

Yaqinda BtpA oqsillari (Btp1/TcpB) eukariotik Toll/interleykin-1 retseptorlari, TIR domeni bilan gomologiyaga ega bakterial oqsillar sinfiga mansubligi va brucellaning makroorganizm hujayralariga penetratsiyasi bilan ajralib chiqishi aniqlangan [24, 25, 35].

Konservativ TIR domeni eukaryotik TLR oqsillarida va immun signalizatsiyasida muhim rol o'ynaydigan MAL (MyD88) sitozolik adapter oqsilida mavjud. Ushbu *Brucella* effektor oqsillari MAL signal o'tkazuvchan adapter oqsilining degradatsiyasiga olib keladi, bu esa TLR2 va TLR4 signallarining ingibitsiyasiga va NF- $\kappa$ B transkripsiya faktorining faollashmasligiga olib keladi. Natijada, yallig'lanishga qarshi muhim TNF-alfa va IL-12 sitokinlarining ishlab chiqarilishi pasayadi, dendritik hujayralarning yetilishi va faollashishi kechikadi, bu infeksiyaning rivojlanishi va davom etishi uchun sharoit yaratadi [11, 37, 38].

## Xulosa

Xulosa qilib aytganda, brutsella bakteriyalarining makroorganizm hujayrasi ichida uzoq muddat parazitizmi bir qancha bir biriga bog'liq yo'llar orqali amalga oshiriladi. Bugunga qadar o'tkazilgan ilmiy ishlar biz keltirgan izlanishlardan ancha ko'p bo'lib brutsella hayot siklini molekulyar darajada bir muncha keng yoritilgan. Ammo hanuz to'liq tasavvur mavjud emaski, biz ushbu infektsiya ustidan to'liq nazorat o'rnatish olmaganimiz. Va albatta bakteriyalarning evolyutsiyasi ham to'xtab qolgani yo'q. Natijada bugungacha olinga ma'lumotlar sekin asta eskirib boradi. Olimlar oldida ushbu kasallikni yanada chuqur o'rganish masalasi hali xanuz o'z dolzarbligini yo'qotmaydi.

Hozirgacha ilm-fanning surunkali brutselloz uchun profilaktika choralari qimmat va samarasiz bo'lib, bu holatda bakterial qo'zg'atuvchining barqarorligi uchun javobgar bo'lgan molekulyar mexanizmlarni to'g'ri tushunish kasallikni nazorat qilish, oldini olish uchun innovatsion vositalarni ishlab chiqishda hal qiluvchi ahamiyatga ega bo'ladi.

### ADABIYOTLAR RO'YXATI:

1. Бруцеллёз. Современное состояние проблемы / под ред. Г.Г. Онищенко, А.Н. Куличенко. – Ставрополь: ООО «Губерния», 2019. – 336 с.
2. WHO, 2019
3. Atluri V.L., Xavier M.N., de Jong M.F. et al. Interactions of the human Pathogenic Brucella Species with Their Hosts. *Ann. Rev. Microb.* 2011, 65:523-541.
4. Byndloss M.X., Tsolis R.M. Brucella spp. Virulence Factors and Immunity. *Ann. Rev. Anim. Biosci.* 2016, 4:111-127.
5. Byndloss M.X., Tsolis R.M. Chronic Bacterial Pathogens: Mechanisms of persistence. *Microbiol Spectr.* 2016, 4 (2).
6. Corbel M.J. Brucellosis: an overview. *Emerg. Infect. Dis.* 1997, 3:213-221.
7. Кулаков Ю.К. Молекулярные механизмы персистенции возбудителя бруцеллеза. *Журнал микробиологии, эпидемиологии и иммунобиологии* 2018
8. Xavier M.N., Paxho T.A., den Hartigh A.B. et al. Pathogenesis of Brucella spp. *The Open Vet. Sci. J.* 2010, 4:109-118.
9. Облокулов А.Р., Ниязова Т.А., Мирзажанова Д.Б., Нуруллаев Р.Р. Клиническая эффективность применения эдкистена при первично хроническом бруцеллезе // *Инфекция иммунитет и фармакология*. 2014. № 3-2. С.32.
10. Kulakov Y. K. Molecular aspects of Brucella persistence. // *Mol. Gen. Microbiol. Virusol.* 2016, 1:1-8.
11. Vershilova P.A., Chernisheva M.I., Knyazeva E.N. Pathogenesis and immunology of brucellosis. 1974, Moscow, *Meditsina*.
12. Anderson T.D., Cheville N.F. Ultrastructural morphometric analysis of Brucella abortus infected trophoblasts in experimental placentitis. Bacterial replication occurs in rough endoplasmic reticulum. *Am. J. Pathol.* 1986, 124:226-237.
13. Pizarro-Cerda J., Meresse S., Parton R.G. et al. Brucella abortus transits through the autophagic pathway and replicates in the endoplasmic reticulum of nonprofessional phagocytes. *Infect. Immun.* 1998, 66:5711-5724.
14. Barquero-Calvo E., Chaves-Olarte E., Weiss D.S. et al. Brucella abortus uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection. *PLoS ONE.* 2007, 2:e631.
15. Martirosyan A., Moreno E., Gorvel J.P. An evolutionary strategy for a stealthy intracellular Brucella pathogen. *Immunological Reviews.* 2011, 240:211-234.
16. Starr T., Ng T.W., Wehrly T.D. et al. Brucella intracellular replication requires trafficking through the late endosomal/lysosomal compartment. *Traffic.* 2008, 9:678-694.
17. Starr T., Child R., Wehrly T.D. et al. Selective subversion of autophagy complexes facilitates completion of the Brucella intracellular cycle. *Cell Host Microbe.* 2012, 11: 33-45.
18. De Jong M.F., Rolan H.G., Tsolis R.M. Innate immune encounters of the (Type) 4th kind: Brucella. *Cell Microbiol.* 2010, 12(9): 1195-1202.
19. Conde-Alvarez R., Arce-Gorvel V., Iriarte M. et al. The lipopolysaccharide core of Brucella abortus acts as a shield against innate immunity recognition. *PLoS Pathog.* 2012, 8:e1002675
20. Yang J., Zhao Y., Shao F. Non-canonical activation of inflammatory caspases by cytosolic LPS in innate immunity. *Curr. Opin. Immunol.* 2015, 32:78-83.

21. Terwagne M., Ferooz J., Rolan H.G. et al. Innate immune recognition of flagellin limits systemic persistence of Brucella. *Cell Microbiol.* 2013, 15:942-960.
22. Zhang X., Kimura Y., Fang C. et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. *Blood.* 2007, 110:228-236.
23. Hoffmann E.M, Houle J.J. Failure of Brucella abortus lipopolysaccharide (LPS) to activate the alternative to activate the alternative pathway of complement. *Vet. Immunol. Immunopathol.* 1983, 5:65-76.
24. Macedo G.C., Magnani D.M., Carvalho N.B. et al. Central role of MyD88-dependent dendritic cell maturation and proinflammatory cytokine production to control Brucella abortus infection. *J. Immunol.* 2008; 180:1080-1087.
25. Salcedo S.P., Marchesini M.I., Lelouard H. et al. Brucella control of dendritic cell maturation is dependent on the TIR-containing protein Btp1. *PLoS Pathog.* 2008, 4:e21.
26. Sengupta D., Koblansky A., Gaines J. et al. Subversion of innate immune responses by Brucella through the targeted degradation of the TLR signaling adapter, MAL. *J. Immunol.* 2010, 184:956-964.
27. Delrue R.M., Martinez-Lorenzo M., Lestrade P. et al. Identification of Brucella spp. genes involved in intracellular trafficking. *Cell Microbiol.* 2001, 3:487-497.
28. O'Callaghan D., Cazevieille C., Allardet-Servent A. et al. A homologue of the Agrobacterium tumefaciens VirB and Bordetella pertussis Ptl type IV secretion systems is essential for intracellular survival of Brucella suis. *Mol. Microbiol.* 1999, 33:1210-1220.
29. Den Hartigh A.B., Rolan H.G., de Jong M.F., Tsolis R.M. VirB3-VirB6 and VirB8-VirB11, but not VirB7, are essential for mediating persistence of Brucella in the reticuloendothelial system. *J. Bacteriol.* 2008. 190: 4427-4436.
30. Zygmunt M.S., Hagi S.D., Walker J.V., Elzer P.H. Identification of Brucella melitensis 16M genes required for bacterial survival in the caprine host. *Microbes Infect.* 2006, 8:2849-2854
31. Celli J., de Chastellier C., Franchini D.M. et al. Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. *J. Exp. Med.* 2003, 198: 545-556.
32. De Jong M.F., Starr T., Winter M.G. et al. Sensing of bacterial type IV secretion via the unfolded protein response. *mBio.* 2013, 4:e00418-12.
33. De Jong M.F., Tsolis R.M. Brucellosis and type IV secretion. *Future Microbiol.* 2012, 7(1): 47-58.
34. Ke Y., Wang Y., Li W., Chen Z. Type IV secretion system of Brucella spp. and its effectors. *Front Cell Infect. Microbiol.* 2015, 13, 5:72.
35. Myeni S., Child R., Ng T.W. et al. 2013. Brucella modulates secretory trafficking via multiple type IV secretion effector proteins. *PLOS Pathog.* 9:e1003556.
36. Wattam A.R., Foster J.T., Mane S.P. et al. Comparative phylogenomics and evolution of the Brucellae reveal a path to virulence. *J. Bacteriol.* 2014, 196(5): 920-930.
37. Ахмедова М.Д., Арашова Г.А., Облокулов А.А. Иммунологические показатели при остром бруцеллёзе // Российская научно-практическая конференция с международным участием. 2009. - №1. Часть 1. С. 33-34.
38. Niyazova T. A., Obloqulov A.R., Magzumov H.B., Tokhtamurodov H. D., Treatment optimization in residual brucellosis//New Day in Medicine 2(30)2020 468-471 <https://cutt.ly/mvIKENK>

**Qabul qilingan sana 09.02.2022**